Table 2. Follow-up of 151 Patients with HCC in Compensated Cirrhosis Treated with RFA.
| Characteristics | Value |
| Complete response-no. (%) | 118 (78) |
| after one cycle | 109 (92) |
| after two cycles | 9 (8) |
| Recurrence after compete response-no. (%) | 80 (67.8) |
| local recurrence | 46 (39) |
| distant recurrence | 34 (28.8) |
| Complications after RFA – no. (%) | 5 (4) |
| portal vein thrombosis | 1 (0.8) |
| subcapsular hematoma | 1 (0.8) |
| intrahepatic abscess | 1 (0.8) |
| pleural effusion | 1 (0.8) |
| seeding | 1 (1.8) |
| Other Treatments – no. (%) | 87 (57.6) |
| RFA | 41 (27.1) |
| TACE | 26 (17.2) |
| OLT | 2 (1.3) |
| RFA+TACE | 7 (4.6) |
| Sorafenib | 11 (7.3) |
| Extra-hepatic spread – no. (%) | 11 (7.3) |
| Overall Survival, Median -mo (95% CI) | 47.6 (41–61) |
| Child-Pugh A (n = 122) | 59.4 (48–72) |
| Child-Pugh B (n = 29) | 26 (15–41) |
| Recurrence-Free Survival, Median -mo (95% CI) | 17 (13–21) |
| Death -no. (%) | 71 (47) |
Abbreviations: TACE, Transarterial chemoembolization; OLT, orthotopic liver transplantation; PEI, percutaneous ethanol injection; RFA, radiofrequency thermal ablation; CI, confidence interval.